Table 1.
Characteristics of the patients according to the anterior or non-anterior STEMI location.
| Anterior STEMI (N=47) | Non-anterior STEMI (N=92) | P value | |
|---|---|---|---|
| Clinical Characteristics | |||
| Age (median, IQR) | 54 [49–61] | 56 [50–64] | 0.545 |
| Male (%) | 36 (77%) | 74 (80%) | 0.598 |
| White (%) | 27 (57%) | 60 (65%) | 0.370 |
| Black (%) | 20 (43%) | 32 (35%) | 0.370 |
| BMI (median, IQR) | 30 [26–34] | 30 [26–35] | 0.824 |
| Diabetes mellitus (%) | 14 (30%) | 25 (27%) | 0.746 |
| Hypertension (%) | 28 (60%) | 54 (59%) | 0.921 |
| Tobacco use (%) | 31 (66%) | 49 (53%) | 0.204 |
| Dyslipidemia (%) | 22 (47%) | 49 (53%) | 0.472 |
| Previous history of CABG (%) | 1 (2%) | 5 (5%) | 0.664 |
| Chronic obstructive pulmonary disease (%) | 3 (6%) | 5 5%) | 0.820 |
| Medication at admission | |||
| Beta-Blocker (%) | 10 (21%) | 20 (22%) | 0.949 |
| Aspirin (%) | 11 (23%) | 28 (30%) | 0.382 |
| ACEi/ARB (%) | 9 (19%) | 26 (28%) | 0.241 |
| Statin (%) | 13 (28%) | 30 (3%) | 0.550 |
| Metformin (%) | 6 (13%) | 13 (14%) | 0.824 |
| Colchicine (%) | 0 (0%) | 0 (0%) | - |
| Clinical presentation | |||
| Thrombolysis (%) | 4 (9%) | 10 (11%) | 0.662 |
| Symptoms to balloon time (min) | 140 [80–314] | 180 [125–387] | 0.041 |
| Angiographic data | |||
| Culprit vessel (%) | - | ||
| Left anterior descending | 47 (100%) | 0 (0%) | |
| Circunflex | 0 (0%) | 26 (28%) | |
| Right coronary artery | 0 (0%) | 64 (70%) | |
| Safein vein graft | 0 (0%) | 2 (2) | |
| TIMI flow 0/1 pre-PCI (%) | 42 (89%) | 75 (82%) | 0.230 |
| TIMI flow 3 post-PCI (%) | 45 (96%) | 88 (96%) | 1 |
| Coronary artery stenting (%) | 44 (94%) | 86 (93%) | 0.975 |
| Manual aspiration thrombectomy (%) | 6 (13%) | 15 (16%) | 0.655 |
| Laboratory data (median IQR) | |||
| WBC (x103/L) | 11.1 [8.8–13.8] | 11.1 [8.4–11.1] | 0.974 |
| Creatinine (mg/L) | 0.99 [0.88–1.13] | 0.97 [0.81–1.42] | 0.836 |
| Peak CK-MB (ng/mL) | 187 [42–287] | 108 [49–222] | 0.070 |
| AUC-hsCRP (mg•day/L) | 153 [60–346] | 110 [51–224] | 0.192 |
| Echocardiographic data | |||
| LV Ejection Fraction, % (median, IQR) at baseline | 45 [40–54] | 53 [45–58] | 0.007 |
| LVEDV, ml, at baseline (median, IQR) | 98 [79–120] | 90 [73–115] | 0.379 |
| LVESV, ml, at baseline (median, IQR) | 54 [35–71] | 42 [32–60] | 0.121 |
| Interval change in LVEF %, (median, IQR) | +5% [−1 to 11] | +2% [−3 to +7] | 0.174 |
| Interval changes in LVEDV ml, (median, IQR) | +3 [−8 to +22] | +1 ml [−8 to +14] | 0.655 |
| Interval changes in LVESV, ml (median, IQR) | +2% [−3 to +7] | −0.3 [−14 to +10] | 0.947 |
| Medication at discharge | |||
| Beta-Blockers (%) | 39 (83%) | 82 (89%) | 0.307 |
| Aspirin (%) | 47 (100%) | 92 (100%) | 1 |
| ACEi/ARB (%) | 42 (89%) | 74 (80%) | 0.231 |
| Statin (%) | 46 (98%) | 91 (99%) | 1 |
| Spironolactone (%) | 4 (9%) | 4 (4%) | 0.443 |
| P2Y12 inhibitors (%) | 47 (100%) | 92 (100%) | 1 |
| Clopidogrel (%) | 24 (51%) | 32 (35%) | 0.064 |
| Prasugrel (%) | 10 (21%) | 24 (26%) | 0.532 |
| Ticagrelor (%) | 13 (28%) | 36 (39%) | 0.180 |
Abbreviations: ACEi/ARB: angiotensin converting enzymes inhibitor/ angiotensin II receptor blockers; BMI: body mass index; CABG: coronary artery bypass graft; CK-MB: Creatine kinase-MB; LV: left ventricle; LVEDV: left ventricle end-diastolic volume; LVESV: left ventricle end-systolic volume; hsCRP: high sensitivity C-reactive-protein; IQR: interquartile range; SD: standard deviation; TIMI: Thrombolysis in myocardial infarction; WBC: white blood cell count